|30th September 2020||Robert J. Spiegel||4,130||Grant/award etc.||$0.00|
|15th September 2020||Gregory Gene Freitag||13,046||Exercise of derivative||$3.67||$47,878.82|
|8th September 2020||Andrew Saik||40,000||Open or private purchase||$1.46||$58,480.00|
|27th August 2020||Rosemary A Crane||661||Grant/award etc.||$0.00|
|11th August 2020||Rosemary A Crane||2,860||Open or private sale||$11.90||$34,037.72|
|11th August 2020||Sol J Barer||23,133||Exercise of derivative||$0.00|
|11th August 2020||Rosemary A Crane||7,956||Exercise of derivative||$0.00|
|30th June 2020||Robert J. Spiegel||3,297||Grant/award etc.||$0.00|
|11th June 2020||Sol J Barer||31,388||Exercise of derivative||$0.00|
|11th June 2020||Rosemary A Crane||17,621||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
is a biotechnology company which develops therapies. It is based in San Francisco and has offices in New York and London. The company has been in business for more than 30 years.